Ozempic Linked to 44% Drop in Depression Risk

A drug prescribed for weight loss and diabetes might be quietly transforming mental health outcomes for thousands of patients.

Researchers tracking nearly 100,000 people in Sweden discovered that semaglutide (sold as Ozempic, Wegovy, and Rybelsus) was linked to dramatic reductions in psychiatric hospital visits, depression, and anxiety. The results, published in The Lancet Psychiatry, surprised even the scientists who conducted the study.

During periods when people took semaglutide, their risk of depression dropped by 44% and anxiety by 38%. Psychiatric hospital visits fell by 42% compared to when they weren't using the medication. Even more striking, substance use disorders requiring hospital care or time off work decreased by 47%.

The 13-year study used Swedish national health registers to track more than 20,000 people who used GLP-1 medications between 2009 and 2022. Researchers compared health outcomes during treatment periods versus times without the drugs.

"The association was quite strong," said Research Director Markku Lähteenvuo from the University of Eastern Finland. "It is possible that, in addition to factors such as reduced alcohol consumption or weight loss-related improvements in body image, there may also be direct neurobiological mechanisms involved."

The findings build on earlier research showing GLP-1 medications reduce alcohol use disorder risk. Professor Mark Taylor from Griffith University noted that alcohol-related problems often affect mood and anxiety, so positive effects on mental health weren't completely unexpected. Still, the magnitude of the results caught the team off guard.

Why This Inspires

This research offers hope to millions facing the dual burden of metabolic and mental health conditions. Obesity and diabetes already increase mental health risks, while psychiatric disorders make metabolic problems more likely. Finding a treatment that addresses both creates new possibilities for comprehensive care.

Scientists suspect multiple factors contribute to the mental health benefits. Weight loss may improve body image and self-esteem. Better blood sugar control in diabetes patients might reduce stress. The drugs could also directly affect brain reward systems that regulate mood and addiction.

While this registry-based study can't prove exactly how semaglutide influences mental health, its size and scope provide stronger evidence than previous smaller studies. The research team acknowledges more investigation is needed to fully understand the mechanisms at work.

The discovery transforms how doctors might think about treating patients with overlapping physical and mental health challenges, opening doors to more integrated care approaches.